Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:diamino acid
go back to main search page
Accession:CHEBI:35987 term browser browse the term
Definition:Any amino acid carrying two amino groups.
Synonyms:cyclic_relationship: is_conjugate_acid_of CHEBI:59561


show annotations for term's descendants           Sort by:
 
L-lysine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Egf epidermal growth factor multiple interactions ISO [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Lysine; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Lysine] CTD PMID:22689575 NCBI chr 3:129,677,574...129,755,322
Ensembl chr 3:129,677,565...129,755,316
JBrowse link
lisinopril dihydrate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ace angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 decreases activity ISO Lisinopril analog results in decreased activity of ACE protein CTD PMID:22200082 NCBI chr11:105,967,948...105,989,964
Ensembl chr11:105,967,945...105,989,964
JBrowse link
G Ace2 angiotensin I converting enzyme (peptidyl-dipeptidase A) 2 increases activity
increases expression
ISO Lisinopril results in increased activity of ACE2 protein
Lisinopril results in increased expression of ACE2 mRNA
CTD PMID:15897343, PMID:16221218 NCBI chr  X:164,139,342...164,188,418
Ensembl chr  X:164,139,332...164,188,420
JBrowse link
G Ache acetylcholinesterase multiple interactions EXP
ISO
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Lisinopril inhibits the reaction [Streptozocin results in increased activity of ACHE protein]]; Lisinopril inhibits the reaction [Streptozocin results in increased activity of ACHE protein]
Lisinopril inhibits the reaction [Sodium Fluoride results in decreased activity of ACHE protein]
CTD PMID:23060470, PMID:31710167 NCBI chr 5:137,288,247...137,294,466
Ensembl chr 5:137,287,519...137,294,466
JBrowse link
G Agt angiotensinogen (serpin peptidase inhibitor, clade A, member 8) decreases expression
multiple interactions
increases secretion
decreases secretion
affects response to substance
increases expression
ISO Lisinopril results in decreased expression of AGT protein
[Lisinopril co-treated with Losartan] results in increased expression of AGT mRNA
Lisinopril results in increased secretion of AGT protein alternative form
Lisinopril results in decreased secretion of AGT protein
AGT gene alternative form affects the susceptibility to Lisinopril
Lisinopril results in increased expression of AGT mRNA
CTD PMID:8393685, PMID:8915971, PMID:15897343, PMID:16221218, PMID:16685205 NCBI chr 8:124,556,587...124,569,706
Ensembl chr 8:124,556,534...124,569,706
JBrowse link
G Bcl2 B cell leukemia/lymphoma 2 decreases expression ISO Lisinopril results in decreased expression of BCL2 CTD PMID:10075388 NCBI chr 1:106,538,176...106,714,290
Ensembl chr 1:106,538,178...106,714,274
JBrowse link
G Cd2ap CD2-associated protein multiple interactions ISO Lisinopril inhibits the reaction [Doxorubicin results in increased expression of CD2AP protein] CTD PMID:16636307 NCBI chr17:42,748,887...42,876,707
Ensembl chr17:42,792,951...42,876,665
JBrowse link
G Edn1 endothelin 1 decreases secretion ISO Lisinopril results in decreased secretion of EDN1 protein CTD PMID:19079593 NCBI chr13:42,301,476...42,307,990
Ensembl chr13:42,301,476...42,307,990
JBrowse link
G Gh growth hormone multiple interactions ISO [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein]; [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein]; [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA] CTD PMID:20051877 NCBI chr11:106,300,261...106,303,703
Ensembl chr11:106,300,271...106,301,865
JBrowse link
G H2-M3 histocompatibility 2, M region locus 3 affects expression ISO Lisinopril affects the expression of HLA-G mRNA CTD PMID:25811541 NCBI chr17:37,270,234...37,274,485
Ensembl chr17:37,270,220...37,274,484
JBrowse link
G Havcr1 hepatitis A virus cellular receptor 1 multiple interactions ISO Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HAVCR1 mRNA]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HAVCR1 protein] CTD PMID:19225054 NCBI chr11:46,739,822...46,779,578
Ensembl chr11:46,735,080...46,779,578
JBrowse link
G Hpse heparanase multiple interactions ISO [Spironolactone co-treated with Lisinopril] inhibits the reaction [Doxorubicin results in increased expression of HPSE protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HPSE protein] CTD PMID:19429930 NCBI chr 5:100,679,484...100,719,716
Ensembl chr 5:100,679,484...100,719,716
JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 increases expression ISO Lisinopril results in increased expression of IGFBP1 protein CTD PMID:9663927 NCBI chr11:7,197,787...7,202,546
Ensembl chr11:7,197,782...7,202,546
JBrowse link
G Mmp2 matrix metallopeptidase 2 multiple interactions ISO [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein] CTD PMID:20051877 NCBI chr 8:92,827,290...92,853,421
Ensembl chr 8:92,827,291...92,853,420
JBrowse link
G Mpo myeloperoxidase multiple interactions EXP 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Lisinopril inhibits the reaction [Streptozocin results in increased activity of MPO protein]]; Lisinopril inhibits the reaction [Streptozocin results in increased activity of MPO protein] CTD PMID:23060470 NCBI chr11:87,793,784...87,804,412
Ensembl chr11:87,793,581...87,804,413
JBrowse link
G Nos2 nitric oxide synthase 2, inducible multiple interactions ISO [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA] CTD PMID:20051877 NCBI chr11:78,920,787...78,960,226
Ensembl chr11:78,920,787...78,960,254
JBrowse link
G Nphs2 nephrosis 2, podocin multiple interactions ISO Lisinopril affects the reaction [Doxorubicin results in increased expression of NPHS2 mRNA]; Lisinopril affects the reaction [Doxorubicin results in increased expression of NPHS2 protein] CTD PMID:16636307 NCBI chr 1:156,310,535...156,328,035
Ensembl chr 1:156,310,727...156,328,035
JBrowse link
G Nppa natriuretic peptide type A decreases expression ISO Lisinopril results in decreased expression of NPPA protein CTD PMID:8393685 NCBI chr 4:148,000,722...148,002,074
Ensembl chr 4:148,000,722...148,002,079
JBrowse link
G Ren1 renin 1 structural increases expression
multiple interactions
ISO Lisinopril results in increased expression of REN protein
[Lisinopril co-treated with Losartan] results in increased expression of REN mRNA
Lisinopril results in increased expression of REN mRNA
CTD PMID:2550029, PMID:8915971, PMID:16221218 NCBI chr 1:133,350,674...133,360,320
Ensembl chr 1:133,350,510...133,360,325
JBrowse link
G Timp1 tissue inhibitor of metalloproteinase 1 multiple interactions ISO [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein]; Lisinopril inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein] CTD PMID:20051877 NCBI chr  X:20,870,166...20,874,737
Ensembl chr  X:20,870,166...20,874,735
JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions ISO Lisinopril inhibits the reaction [Doxorubicin results in decreased expression of VEGFA protein] CTD PMID:19293598 NCBI chr17:46,016,993...46,032,377
Ensembl chr17:46,016,993...46,032,369
JBrowse link
royal jelly term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bcl2 B cell leukemia/lymphoma 2 multiple interactions EXP royal jelly inhibits the reaction [Nicotine results in decreased expression of BCL2 mRNA] CTD PMID:30896085 NCBI chr 1:106,538,176...106,714,290
Ensembl chr 1:106,538,178...106,714,274
JBrowse link
G Casp3 caspase 3 multiple interactions EXP royal jelly inhibits the reaction [Nicotine results in increased expression of CASP3 mRNA] CTD PMID:30896085 NCBI chr 8:46,617,291...46,639,698
Ensembl chr 8:46,617,291...46,639,689
JBrowse link
G Cat catalase multiple interactions ISO
EXP
royal jelly inhibits the reaction [Cisplatin results in decreased activity of CAT protein]
royal jelly inhibits the reaction [Nicotine results in decreased activity of CAT protein]
CTD PMID:20369241, PMID:30896085 NCBI chr 2:103,453,904...103,485,153
Ensembl chr 2:103,453,849...103,485,160
JBrowse link
G Cyp4a14 cytochrome P450, family 4, subfamily a, polypeptide 14 affects expression EXP royal jelly affects the expression of CYP4A14 mRNA CTD PMID:16161764 NCBI chr 4:115,486,200...115,496,158
Ensembl chr 4:115,486,200...115,496,142
JBrowse link
G Esr1 estrogen receptor 1 (alpha) multiple interactions
increases activity
affects binding
ISO Estradiol inhibits the reaction [royal jelly binds to ESR1 protein]; royal jelly binds to and results in increased activity of ESR1 protein; royal jelly inhibits the reaction [Estradiol binds to ESR1 protein]
royal jelly results in increased activity of ESR1 protein
CTD PMID:15946813, PMID:17287592 NCBI chr10:4,611,989...5,005,633
Ensembl chr10:4,611,593...5,005,614
JBrowse link
G Esr2 estrogen receptor 2 (beta) multiple interactions
affects binding
ISO Estradiol inhibits the reaction [royal jelly binds to ESR2 protein]; royal jelly binds to and results in increased activity of ESR2 protein; royal jelly inhibits the reaction [Estradiol binds to ESR2 protein] CTD PMID:15946813, PMID:17287592 NCBI chr12:76,120,419...76,177,259
Ensembl chr12:76,120,419...76,177,259
JBrowse link
G Pcna proliferating cell nuclear antigen multiple interactions EXP royal jelly inhibits the reaction [Nicotine results in decreased expression of PCNA protein] CTD PMID:30896085 NCBI chr 2:132,249,286...132,253,180
Ensembl chr 2:132,249,162...132,253,314
JBrowse link
G Tff1 trefoil factor 1 increases expression ISO royal jelly results in increased expression of TFF1 mRNA CTD PMID:15946813 NCBI chr17:31,161,395...31,165,060
Ensembl chr17:31,161,395...31,165,277
JBrowse link
G Trp53 transformation related protein 53 multiple interactions EXP royal jelly inhibits the reaction [Nicotine results in increased expression of TRP53 mRNA] CTD PMID:30896085 NCBI chr11:69,580,348...69,591,873
Ensembl chr11:69,580,359...69,591,873
JBrowse link
G Vegfa vascular endothelial growth factor A increases expression ISO royal jelly results in increased expression of VEGFA mRNA CTD PMID:15946813, PMID:17287592 NCBI chr17:46,016,993...46,032,377
Ensembl chr17:46,016,993...46,032,369
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 21475
    role 21452
      application 20933
        refrigerant 18561
          ammonia 17665
            organic amino compound 17664
              amino acid 14568
                diamino acid 29
                  (2R,5S)-2,5-diaminohexanoic acid 0
                  (3R)-3,6-diaminohexanoic acid 0
                  (3S)-3,6-diaminohexanoic acid 0
                  (3S)-3,7-diaminoheptanoic acid 0
                  (3S,5S)-3,5-diaminohexanoic acid 0
                  2,4-diaminobutyric acid + 0
                  2,4-diaminopentanoic acid + 0
                  2,6-diamino-7-hydroxy-azelaic acid 0
                  3-aminoalanine + 0
                  L-BMAA 0
                  lysine + 29
Path 2
Term Annotations click to browse term
  CHEBI ontology 21475
    subatomic particle 21460
      composite particle 21460
        hadron 21460
          baryon 21460
            nucleon 21460
              atomic nucleus 21460
                atom 21460
                  main group element atom 21361
                    p-block element atom 21361
                      carbon group element atom 21148
                        carbon atom 21046
                          organic molecular entity 21046
                            organic group 19485
                              organic divalent group 19475
                                organodiyl group 19475
                                  carbonyl group 19452
                                    carbonyl compound 19452
                                      carboxylic acid 19065
                                        amino acid 14568
                                          diamino acid 29
                                            (2R,5S)-2,5-diaminohexanoic acid 0
                                            (3R)-3,6-diaminohexanoic acid 0
                                            (3S)-3,6-diaminohexanoic acid 0
                                            (3S)-3,7-diaminoheptanoic acid 0
                                            (3S,5S)-3,5-diaminohexanoic acid 0
                                            2,4-diaminobutyric acid + 0
                                            2,4-diaminopentanoic acid + 0
                                            2,6-diamino-7-hydroxy-azelaic acid 0
                                            3-aminoalanine + 0
                                            L-BMAA 0
                                            lysine + 29
paths to the root

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.